From: Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
(a) Injection site | ||||||
Dose | Abdomen | Forearm | n | |||
First | 0 | 29 (100.0) | 29 | |||
Second | 6 (21.4) | 27 (96.4) | 28 | |||
Third | 0 | 19 (100.0) | 19 | |||
Forth | 0 | 19 (100.0) | 19 | |||
(b) Degree of Injection site reaction | ||||||
Dose | None | Mild | Moderate | Severe | n | |
First | 20 (71.4) | 7 (25.0) | 1 (3.6) | 0 | 28 | |
Second | 20 (71.4) | 6 (21.4) | 1 (3.6) | 1 (3.6) | 28 | |
Third | 13 (68.4) | 3 (15.8) | 2 (10.5) | 1 (5.3) | 19 | |
Forth | 13 (68.4) | 3 (15.8) | 3 (15.8) | 0 | 19 | |
(c) Types of Injection site reaction | ||||||
Dose | Pain | Redness | Swelling | Numbness | Others | n |
First | 3 (10.7) | 1 (3.6) | 6 (21.4) | 2 (7.1) | 0 | 28 |
Second | 3 (10.7) | 3 (10.7) | 6 (21.4) | 0 | 1 (3.6) | 28 |
Third | 2 (10.5) | 4 (21.1) | 4 (21.1) | 0 | 2 (10.5) | 19 |
Forth | 1 (5.3) | 4 (21.1) | 6 (31.6) | 0 | 3 (15.8) | 19 |